GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Median PS Value

ChemoCentryx (ChemoCentryx) Median PS Value : $0.00 (As of Apr. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. ChemoCentryx's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $0.528. ChemoCentryx's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-25), ChemoCentryx's share price is $51.99. ChemoCentryx's Median PS Value is $0.00. Therefore, ChemoCentryx's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for ChemoCentryx's Median PS Value or its related term are showing as below:

CCXI's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

ChemoCentryx Median PS Value Historical Data

The historical data trend for ChemoCentryx's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Median PS Value Chart

ChemoCentryx Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ChemoCentryx Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ChemoCentryx's Median PS Value

For the Biotechnology subindustry, ChemoCentryx's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoCentryx's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChemoCentryx's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where ChemoCentryx's Price-to-Median-PS-Value falls into.



ChemoCentryx Median PS Value Calculation

ChemoCentryx's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.528*0
=0.00

10-Year Median PS Ratio is 0.
ChemoCentryx's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.528.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoCentryx  (NAS:CCXI) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

ChemoCentryx's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=51.99/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoCentryx Median PS Value Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoCentryx (ChemoCentryx) Business Description

Traded in Other Exchanges
N/A
Address
835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Executives
Susan M Kanaya officer: SVP Finance, CFO & Secretary 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall director, 10 percent owner, officer: President, CEO and Director 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau officer: SVP, Finance & Acctg Officer C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt officer: EVP, Chief Operating Officer C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards director C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel officer: CBO and Treasurer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan officer: Principal Acctg Officer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh officer: SVP, Research C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027

ChemoCentryx (ChemoCentryx) Headlines

From GuruFocus

ChemoCentryx Spikes 110% on Amgen Acquisition Deal

By Margaret Moran 08-04-2022